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Abstract
Background: The high incidence of cardiovascular disease in patients with end stage renal disease
(ESRD) is related to the accumulation of uremic toxins in the middle and large-middle molecular
weight range. As online hemodiafiltration (HDF) removes these molecules more effectively than
standard hemodialysis (HD), it has been suggested that online HDF improves survival and
cardiovascular outcome. Thus far, no conclusive data of HDF on target organ damage and
cardiovascular morbidity and mortality are available. Therefore, the CONvective TRAnsport
STudy (CONTRAST) has been initiated.
Methods: CONTRAST is a Dutch multi-center randomised controlled trial. In this trial,
approximately 800 chronic hemodialysis patients will be randomised between online HDF and low-
flux HD, and followed for three years. The primary endpoint is all cause mortality. The main
secondary outcome variables are fatal and non-fatal cardiovascular events.
Conclusion: The study is designed to provide conclusive evidence whether online HDF leads to
a lower mortality and less cardiovascular events as compared to standard HD.
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Atherosclerotic cardiovascular disease (CVD) is common
among hemodialysis (HD) patients. In fact, approxi-
mately 50% of the deaths is attributed to cardiovascular
causes, which is much higher than in the general popula-
tion [1]. In addition, chronic HD patients suffer from
atherosclerotic complications at a relatively younger age
and die younger from ischemic heart disease [2]. The ori-
gin of CVD in chronic HD patients is most probably
multi-factorial, as the extremely high prevalence in this
patient group is not easily explained by traditional risk
factors, either alone or in combination [3]. In recent years,
other contributing factors have emerged, including the
accumulation of uremic toxins, disturbances in the
immuno-inflammatory system, as reflected by a chronic
micro-inflammatory state, increased oxidative stress, and
endothelial dysfunction [4-6]. In particular the retention
of larger uremic toxins, the so-called middle molecules
(MM, molecular weight [MW] 0.5 – 50 kDa), may play an
important role in the pathogenesis of CVD [7,8]. There-
fore, it is conceivable that dialysis modalities with supe-
rior MM removal reduce CVD and improve survival.
In contrast to diffusive dialysis strategies, which mainly
remove small MW solutes, such as urea and creatinine,
convective dialysis strategies are particularly effective in
the removal of larger molecules. In hemodiafiltration
(HDF), diffusive and convective transport are combined,
providing an optimal removal of both small and larger
MW substances up to the range of 30 – 40 kDa. Clinical
studies have shown that beta-2-microglobulin (β2 m),
which is a typical MM with a MW of 11.8 kDa and there-
fore incapable of passage through the membrane of low
flux devices, is effectively removed during HDF leading to
lower pre-dialysis levels in the long term [9,10]. Similarly,
the removal of other MM such as advanced glycation end-
products (AGEs), leptin, and complement factor D is
enhanced by convective transport [11-13]. Apart from the
increased MM clearance, it has been suggested that HDF
improves the removal of smaller molecules that are highly
protein bound, due to a better elimination of the
unbound fraction [14]. With respect to homocysteine,
which is >90% protein bound, the observed decrease may
also be explained by an improved removal of uremic sub-
stances with inhibitory effects on its metabolism [15].
Finally, it has been shown that treatment with online HDF
leads to lower plasma phosphate concentrations, as com-
pared to standard HD [16,17].
At present, it is unclear whether HDF has a favourable
effect on the micro-inflammatory state in dialysis patients.
Although a reduction of pro-inflammatory proteins has
been shown during HDF [18], anti-inflammatory
cytokines may also be removed. Of note, besides solute
removal, other factors may influence the inflammatory-
state as well, such as the bio-incompatibility of the dia-
lyser membrane and the microbiological quality of the
dialysate [19,20]. Considering oxidative stress and
endothelial dysfunction, data on the effects of HDF on
these parameters are limited.
In summary, compared to standard HD, HDF improves
the uremic state by an increased clearance of MM and
other, mainly protein bound, uremic toxins. Circumstan-
tial evidence implies that these effects result in less vascu-
lar damage and ultimately in decreased cardiovascular
morbidity and mortality (figure 1). Although observa-
tional studies suggest that online HDF improves cardio-
vascular outcome in chronic HD patients [21,22], two
small randomised studies failed to show any differences
between online HDF and standard HD [23,24]. However,
the latter analysis lacked adequate power to detect differ-
ences in clinical endpoints.
Based on the above-mentioned theoretical considera-
tions, the scarcity of reliable clinical data, and the growing
interest in convective techniques under nephrologists, the
CONvective TRAnsport STudy (CONTRAST) has been ini-
tiated. CONTRAST is a randomised controlled trial inves-
tigating the effects of online HDF on clinical endpoints,
compared to low-flux HD. If online HDF indeed leads to
an improvement in CV morbidity and mortality, this find-
ing will imply a breakthrough in the treatment of chronic
HD patients.
Methods
Objectives
The primary objective of CONTRAST is to assess the effect
of on-line HDF on all cause mortality, when compared to
HypothesisFigure 1
Hypothesis
Decreased cardiovascular morbidity and mortality
Decreased vascular damage
Superior correction of uremia
Increased convective transport by online HDFPage 2 of 10
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fatal and non-fatal cardiovascular events. Other secondary
outcome measures include differences between treatment
regimens on the progression of left ventricular mass index
(LVMi), as assessed by echocardiography, the progression
of atherosclerosis as assessed by measurement of carotid
intima-media thickness (CIMT) and the progression of
arterial stiffness, as assessed by measurement of aortic
pulse wave velocity (PWV). Furthermore, several labora-
tory markers of endothelial function, inflammatory state,
and oxidative stress will be assessed over time and com-
pared between the two treatment groups. In addition, sub-
jective global assessment (SGA) is performed in the study
patients as a measure of nutritional state, and a question-
naire is used to investigate the effects of on-line HDF on
quality of life.
Study design
In this randomised controlled trial, participants are ran-
domised centrally into a 1:1 ratio for treatment with
online HDF or treatment with low-flux HD.
Randomisation is stratified by the participating centres
and occurs in blocks. The follow-up period is three years.
At present, 24 dialysis centres have agreed to recruit the
required number of patients. The study is conducted
according to good clinical practice (GCP) guidelines.
Patients
The in- and exclusion criteria are given in table 1. Since the
study results may be of importance for chronic HD
patients of all ages, no upper age limit has been set. Severe
incompliance is defined as non-adherence to the dialysis
prescription, especially the frequency and duration of
dialysis treatment. Permission for participation in other
(e.g. observational) studies will be discussed with and
decided by the executive committee.
Stabilisation period
Before randomisation, patients will be dialysed 3 times
(or 2 times) per week with low-flux synthetic dialysers
(UF-coefficient < 20 ml/mmHg/h) for at least 6 months in
case of a prevalent dialysis patient and at least 2 months
in case of a new dialysis patient.
Blood flow will be maintained at 250–400 ml/min. Anti-
coagulation is performed with low molecular weight
heparin (LMWH) before HD. Patients on coumarins
receive 50% of the LMWH dose. Treatment times will be
adapted to a target dialysis spKt/V urea of ≥ 1.2 per treat-
ment. Ultra pure water is used for preparation of dialysis
fluid. Bicarbonate is provided from powder cartridges to
avoid the risk of a bacterial load from bicarbonate concen-
trates. For instance, the biBAGR system (Fresenius) and
BiCartR system (Gambro) will be used. The dialysate flow
is 500 ml/min and the temperature of the dialysate is
36°C.
Routine patient care
Metabolic control will be performed according to the
guidelines of the Quality of Care Committee of the Dutch
Federation of Nephrology. Anti-hypertensive medication,
lipid lowering therapy, platelet aggregation inhibitors and
medication to treat renal anemia and renal osteodystro-
phy will also be prescribed according to these guidelines,
and, if not available, according to usual care.
Randomisation
The patients will be randomised as soon as they are con-
sidered to be stable. When a patient has been randomised
for low-flux HD, the treatment as performed in the stabi-
lisation period will be continued. Treatment times will be
adjusted only if dialysis spKt/V urea < 1.2 per treatment or
if ultrafiltration goals can not be achieved, according to
the attending nephrologist. When randomised for online
HDF, patients will be treated with a target post-dilution
dose of 6 l/h (~100 ml/min) and a high-flux synthetic dia-
lyser (UF-coefficient > 20 ml/mmHg/h). Blood flow will
be set at >300 ml/min, if possible, in order to achieve a
substitution volume of 100 ml/min. If the blood flow is
less than 300 ml/min, the post-dilution volume will be
decreased accordingly (filtration and post-dilution <25–
33% of blood flow). If necessary, the dose of LMWH will
be increased and given in two separate doses. Treatment
times will be fixed according to the prescription in the sta-
bilisation period and adjusted only when spKt/V urea is <
1.2 / treatment. Metabolic control and medication is sim-
ilar to the low-flux group, as described above.
Table 1: Inclusion and exclusion criteria
Inclusion criteria
patients treated by HD 2 or 3 times a week, for at least 2 months.
patients able to understand the study procedures.
patients willing to provide written informed consent.
Exclusion criteria
current age < 18 years
treatment by HDF or high flux HD in the preceding 6 months
severe incompliance
life expectancy < 3 months due to non renal disease
participation to other clinical intervention trials evaluating 
cardiovascular outcomePage 3 of 10
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Dialysers with comparable biocompatible membrane
material and surface area will be used in both treatment
groups, to ascertain that differences in clearance result
from differences in convective transport, rather than dif-
ferences in dialyser characteristics. Only if the target dose
of 6 l/h post-dilution is not achieved in the online HDF
patients, it is allowed to prescribe a membrane with a
larger surface area. The membranes advised by the study
group are summarised in table 2. As many low-flux mem-
branes with a membrane surface > 1.5 m2 have a UF coef-
ficient 10–20 ml/mmHg/h, in this study low-flux is
defined as a UF coefficient of < 20 ml/mmHg/h.
Online HDF technique
During hemodiafiltration, the removal of larger solutes is
increased by excess ultrafiltration, leading to solute
removal by convection. As fluid removal exceeds the
desired weight loss of the patient, fluid balance is main-
tained by the infusion of a pyrogen-free substitution solu-
tion. In addition, dialysate is used to create a
concentration gradient for solute removal by diffusion, as
in standard HD. At the introduction of HDF more than 20
years ago, the substitution fluid was supplied in bags. The
infusion volumes were limited due to the high costs and
laborious procedure, limiting the efficiency of HDF.
In recent years, however, technical advances have made it
possible to prepare the substitution solution online from
ultra pure water and dialysate concentrates. As a result, the
volume of the substitution fluid could be increased con-
siderably, without the disadvantages of inconvenient
bags. Hence, the UF rate can be increased up to 50L per
treatment in the pre-dilution mode and 25L in the post-
dilution mode [25].
Online dialysate and substitution fluid preparation
Ultra-pure water is used for the preparation of bicarbo-
nate-containing dialysis fluid, which undergoes one step
of ultrafiltration converting it into ultra pure dialysis
fluid. Dialysis fluid is produced at a rate of 600–800 ml/
min of which approximately 100 ml/min is diverted for
further processing into substitution fluid. The electrolyte
composition of the dialysis fluid is: Na+ 138–140 mmol/
l; K+ 1.0–3.0 mmol/l; HCO3 - 30–35 mmol/l; Ca++ 1.0–1.7
mmol/l; Mg++ 0.5 mmol/l; Cl- 108–109.5 mmol/l; glucose
0–5.6 mmol/l; acetate 3 mmol/l.
The substitution fluid is prepared from the dialysis fluid
by one additional step of controlled ultrafiltration, before
it is infused post-filter into the blood. The electrolyte com-
position of the substitution fluid is the same as the
composition of the dialysis fluid. Ultrafiltration proce-
dures will be performed according to the manufacturers'
instructions, as described below.
- The on-line system, ONLINEplus™ (Fresenius Medical
Care, Bad Homburg, Germany) is integrated into the dial-
ysis machine (4008 series; Fresenius Medical Care) and
consists of two ultrafilters (DIASAFE® plus), an infusate
pump module, and disposable infusate lines. Infusate is
prepared continuously by double-stage ultrafiltration.
Both filters are subjected to automated membrane integ-
rity tests before dialysis, and are replaced after 100 treat-
ments or 12 weeks of use, whichever comes first. Dialysis
fluid downstream from the first filter stage enters the dia-
lyser; part of the stream is subjected to cross-flow filtration
in the second filter in order to produce infusate. The infu-
sate stream is connected with the venous bubble catcher
for post-dilution HDF [25,26].
- The AK 100/200 ULTRA dialysis machine (Gambro AB,
Lund, Sweden) prepares ultra pure water and ultra pure
dialysis fluid by stepwise ultrafiltration of water and bicar-
Table 2: Dialyser characteristics for both treatment arms
Low-flux HD Online HDF
Company Gambro Fresenius Gambro Fresenius
Dialyser Polyflux 17L F8HPS Polyflux 170H FX80
Membrane material polyamide polysulfone polyamide polysulfone (helixone)
Sterilisation method heat heat heat heat
Surface area (m2 ) 1.7 1.8 1.7 1.8
Membrane thickness (µm) 50 40 50 35
UF coefficient (ml/mmHg/h) 13 18 65 59
In vitro clearance:# 
Urea 260 251 268 276
Phosphate 198 193 229 239
Vit B12 111 118 158 175
# (QB = 300 ml/min, QD = 500 ml/min)Page 4 of 10
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polyamide ultrafilters (U8000 S). When used for HDF,
sterile non-pyrogenic solution is prepared on-line from
the ultra pure dialysis fluid by an additional step of ultra-
filtration using a sterile polyamide ultrafilter (U2000)
integrated in a sterile line set (Steriset). The hygiene of the
fluid pathway, including the U8000S ultrafilters, will be
assured by heat disinfections after each treatment. The
U8000S filters are changed bimonthly. The final ultrafilter
(U2000) is employed on a single-use basis [26,25].
Data collection
Baseline and follow-up data registration
At baseline, all relevant information will be documented:
i.e. demographical data, information on cardiovascular
risk factors, time on dialysis, cause of renal insufficiency,
and medication. A follow-up visit will be scheduled every
three months. During this visit, the occurrence of CV
events, death, and hospitalisation will be documented. In
addition, blood pressure, body weight and the achieved
filtration and substitution dose per treatment will be reg-
istered. Case record forms are provided using the Tele-
Form system (version 8.1.1, Cardiff Software Inc, Vista,
CA, USA). As all completed forms are scanned, no data
entry by typing is needed. Registration of all data will be
performed in each centre by the attending nephrologists
and research nurses.
Recording outcome events
CV events include fatal or non-fatal myocardial infarction,
stroke, therapeutic coronary procedure (PTCA or stent-
ing), therapeutic carotid procedure (endarterectomy or
stenting), and PTA and vascular intervention
(revascularisation, PTA or stenting). Congestive heart fail-
ure is excluded as a CV event, since the discrimination
with fluid overload is often hard to make in chronic HD
patients. Furthermore, hospitalisations, duration of the
hospitalisations and main diagnosis (including the occur-
rence of infections) will be recorded during the study
period.
An independent event committee will evaluate all causes
of death, cardiovascular events, and infections. The pri-
mary investigators will collect sufficient information of
the events for the event committee. The event committee
is blinded for information on the received treatment and
consists of physicians with different specialisations: neu-
rologists, vascular surgeons, nephrologists, internists, and
cardiologists. Events will be coded as fatal and non-fatal,
definite, probable and possible and not codeable (i.e.
insufficient information). Only definite and probable
events will be used in the final analysis. This procedure is
successfully applied in a number of studies coordinated
by the Julius Center, e.g. in the SMART study [27].
Left ventricular hypertrophy
Using transthoracic M-mode echocardiography from the
parasternal long axis position, left ventricular end-diasto-
lic diameter (LVEDD), end-systolic diameter (LVESD) as
well as posterior and septal wall thickness will be deter-
mined at baseline, after 6 months, after 12 months and
annually afterwards, on a midweek non-dialysis day
according to a central uniform protocol. From these
parameters left ventricular ejection fraction (LVEF) will be
determined as LVEDD – LVESD/LVEDD, while the left
ventricular mass index (LVMi) will be calculated using the
formula of Devereux and Reichek [28], modified in
accordance with the recommendations of the American
Society of Echocardiography [29]. The ultrasound investi-
gations will be recorded on a compact disc and analysed
off-line by experienced cardiologists in a core laboratory.
Vessel wall measurements
With respect to carotid intima-media thickness (CIMT),
the outcome is the change in mean common CIMT,
defined as the average of the intima-media thickness
measurements performed circumferentially at pre-defined
angles for the near and far wall of 10 mm segments of the
right and left distal common carotid arteries [30]. A lim-
ited number of centres will be involved in the CIMT meas-
urements in this study. Centres will be trained according
to a central uniform carotid ultrasound protocol. Before
actually starting the study, sonographers need to be certi-
fied as outlined in the CIMT ultrasound protocol.
Measurements will be performed at baseline and then
annually on a midweek non-dialysis day. The ultrasound
scan is being recorded on videotape and analysed off line
by a core laboratory. Quality Assurance and Quality Con-
trol procedures as existing and applied in several
(inter)national trials will be implemented [31,32].
Pulse wave velocity (PWV) is determined to provide addi-
tional information on functional changes of the arterial
wall [33]. The outcome measurement is the change in aor-
tic PWV. A limited number of centres will be involved in
the PWV measurements in this study. Centres will be
trained according to a central uniform PWV protocol.
Data are checked regularly on quality control aspects as
defined in the PWV protocol as described earlier [34].
Measurements will be performed at baseline and then
annually on a midweek non-dialysis day.
Nutritional state
At base-line, after 1, 2 years and at the end of the study,
nutritional state is assessed by subjective global assess-
ment (SGA), pre-albumin and dry weight [35].Page 5 of 10
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Patient well-being will be estimated at baseline, and once
a year by the Kidney Disease Quality of Life Short Form
(KDQOL-SF). This version is validated in American and
Dutch dialysis patients [36,37].
Laboratory assessments
Three monthly, blood samples will be drawn for routine
laboratory assessments. In addition, blood samples will
be taken at baseline, and after 6, 12, 18, 24, and 36
months for determinations of oxidative stress, inflamma-
tory and endothelial function markers. Finally, a whole
blood sample will be stored for future research on the
effect of genetics on the response to HDF, after specific
permission of the patients in the informed consent form.
Statistical methods
The results of the study will be analysed according to the
'intention to treat' principle.
Primary outcome
The primary outcome variable is the time until the occur-
rence of an event defined as 'all cause mortality'. Results
will be presented as Kaplan-Meier curves for the two
treatment arms and the difference between the two treat-
ments will be analysed using a log-rank test. The log-rank
test will be adjusted for the effect of cumulative data anal-
yses (see below).
Secondary outcomes
CV events are considered as secondary outcome variables.
They will be analysed and presented as described for the
primary outcome variable.
The primary analysis of CIMT progression will employ a
linear random coefficient (Laird-Ware) model using real
visit days, treatment and clinical center as independent
variables. for each participant, the intercept and slope of
CIMT change over time is assumed to be a normally dis-
tributed random variable with different means for the two
treatment groups. The mean slope for the HDF treatment
group will be compared to that for the low flux group
using linear contrasts and a 5% significance level. Addi-
tional exploratory analyses will evaluate the impact of
including baseline CIMT, lumen diameter, and ultra-
sound reader as additional co-variates.
The data analytic approach to arrive at the PWV outcome
variable and the LVMi outcome variable is similar to that
of the CIMT outcome. Adjustments that will be taken into
account in the estimates are changes in MAP and changes
in heart rate, since both are closely related to PWV.
Sample size considerations
The sample size of the present study is based on the fol-
lowing event rates: the 3-year all cause mortality rate
among subjects with ESRD is 44% based on data from the
Dutch renal replacement registry (RENINE) [38]. CV mor-
tality constitutes 40–60% of the total group of deaths,
leading to a 3 year CV mortality rate of 22% in HD
patients. Assuming that the incidence of non-fatal CVD is
equal to the CV mortality rate (22%), the three-year inci-
dence of fatal and non-fatal CVD is 44%. In addition,
based on experience ± 8% of the ESRD patients will
undergo renal transplantation yearly and as such is being
censored in the trial.
Assuming that HDF will reduce all cause mortality with
20%, it has been estimated that with a two-sided alpha of
0.05 and a power of 80%, about 772 patients need to be
enrolled and followed for three years. In these patients
about 250 events are expected to come to a decision. Note
that the total number of patients to be included cannot be
specified in advance because of the planned sequential
interim analyses, as described below.
Interim analysis
In this study, group sequential interim analyses will be
performed to evaluate the primary outcome variable. The
reason for this approach is that, on average, fewer patients
are needed in the study when the expected difference in
the primary outcome variable is real or when no differ-
ence of the hypothesised magnitude can be expected
anymore.
Sequential analysis is a statistical approach where one
conducts significance tests over time as the data are col-
lected. Sequential analysis and its application in clinical
trials have been described extensively by Whitehead [39].
Sequential design and analysis is implemented in the
computer program PEST version 4 [40].
The general approach is as follows. A null hypothesis H0
and an alternative hypothesis H1 are formulated for a suit-
able measure θ of treatment difference. For this study with
a survival type outcome variable, θ is equal to the negative
of the logarithm of the hazard ratio (HR). The HR is
defined as the ratio of the logarithm of the (expected)
cumulative survival under HDF (= 0.648) and the loga-
rithm of the (expected) cumulative survival under HD (=
0.56). H0 is formulated as "no difference in the occurrence
of the primary endpoint between the two trial arms" or θ
= 0 (i.e. HR = 1). The alternative hypothesis H1 is formu-
lated as |θ| ≥ -log(0.75) = 0.29. Two test statistics, Z and V,
can be derived depending on the type of response varia-
ble. Z is a measure of the treatment difference; for survival
data Z is the observed number of events in the control
group minus the expected number of events given treat-Page 6 of 10
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about θ contained in Z; for survival data V is approxi-
mately equal to a quarter of the number of events
observed. The sequential analysis requires critical bound-
aries to be specified in advance. These boundaries depend
on θ, the type I error α and the power 1-β. For each new
group of patients, values of Z and V are calculated and pre-
sented graphically by plotting Z against V (see Fig. 2 for an
illustration of a double-sided sequential test). Based on
the path of cumulative (Z,V)-points, one of the following
three decisions is made:
1) the upper or the lower (continuous) boundary is
crossed: stop the data collection and reject the null
hypothesis;
2) one of the inner wedge-shaped (dashed) boundaries is
crossed: stop the data collection and accept the null
hypothesis;
3) continue the data collection: the cumulative data are
inadequate to draw a conclusion yet.
Sequential analysisFig re 2
Sequential analysis. Boundaries for a double sequential triangular test with α = 0.05, power 0.80 and hazard ratio 0.75. Z is 
the observed number of events in the control group minus the expected number of events given treatment equivalence. V is 
approximately equal to a quarter of the number of events observed.Page 7 of 10
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(DSMB) will evaluate the results of the sequential interim
analyses. The DSMB consists of a biostatistician (chair), a
nephrologist, an internist, and a clinical epidemiologist.
The biostatistician will perform the sequential analyses.
The executive committee will provide the DSMB every 2
months with the relevant database to perform the
unblinded analyses. The main task of the DSMB is to
decide whether the analyses provide enough evidence of
either efficacy or no efficacy with respect to the primary
outcome and formulates recommendations for the execu-
tive committee on the continuation of the trial. The DSMB
may also offer unsolicited recommendations on the
continuation of the trial, for example after publication of
results of similar trials.
Conclusion
Online HDF is gaining popularity, as recent technical
advances have made it possible to safely replace consider-
able amounts of fluid at reasonable cost. In addition,
accumulating evidence indicates that the correction of the
uremic state is improved by online HDF, if compared to
standard HD. However, at present it is unclear whether
long-term treatment with HDF ultimately results in an
improved clinical outcome. Therefore, CONTRAST is ini-
tiated, a randomised controlled trial of sufficient sample
size to detect differences in survival and cardiovascular
events. Patients will be randomised between low-flux HD
and online HDF and followed for 3 years. Over 20 Dutch
dialysis centers participate in this study and approxi-
mately 800 incident and prevalent HD patients will be
recruited. By April 2005, more than 150 patients were
included.
Appendix
Steering committee
The steering committee consists of the primary investiga-
tors (nephrologists) of the participating centers. The
members and institutions in the Netherlands are:
W. Bax, Medical Center Alkmaar, Alkmaar;
W.H. Boer, University Medical Center Utrecht, Utrecht;
H. Boom, Reinier de Graaf Hospital, Delft;
G.J. Bruinings, Slingeland Hospital, Doetinchem;
M. van Buren, Leyenburg Hospital, The Hague;
G.W. Feith, Gelderse Vallei Hospital, Ede;
A.B. Geers, St Antonius Hospital, Nieuwegein;
J.O. Groeneveld, Onze Lieve Vrouwe Gasthuis,
Amsterdam;
H.W. van Hamersvelt, University Medical Center St Rad-
boud, Nijmegen;
F. de Heer, Maasland Hospital, Sittard;
B.C. van Jaarsveld, Dianet Dialysis Centers, Utrecht;
M.G. Koopman, Academic Medical Center, Amsterdam;
A.T. Lavrijssen, Oosterschelde Hospital, Goes;
C.J. Konings, Catharina Hospital, Eindhoven;
M.I. Koolen, Jeroen Bosch Hospital, 's Hertogenbosch;
T.K. Kremer Hovinga, Martini Hospital, Groningen;
W.H. van Kuijk, VieCuri Medical Center, Venlo;
J.J. Offerman, Isala Clinics, Zwolle;
L.J. Reichert, Rijnstate Hospital, Arnhem;
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